Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis

Eun Ho Kim, Hyo Sook Song, Seung Hoon Yoo, Myonggeun Yoon

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Treatment with alternating electric fields at an intermediate frequency (100-300 kHz), referred to as tumor treating fields (TTF) therapy, inhibits cancer cell proliferation. In the present study, we demonstrated that TTF application suppressed the metastatic potential of U87 and U373 glioblastoma cell lines via the NF-kB, MAPK and PI3K/AKT signaling pathways. Wound-healing and transwell assays showed that TTF suppressed cell migration and invasion compared with controls. Soft agar and three-dimensional culture assays showed that TTF inhibited both anchoragedependent (cell proliferation) and anchorage-independent (colony formation) GBM cell growth. TTF dysregulated epithelial-to-mesenchymal transition-related genes, such as vimentin and E-cadherin, which partially accounted for TTF inhibition of cell migration and invasion. We further demonstrated that TTF application suppressed angiogenesis by downregulating VEGF, HIF1a and matrix metalloproteinases 2 and 9. TTF also inhibited NF-kB transcriptional activity. Collectively, our findings show that TTF represents a promising novel anti-invasion and anti-angiogenesis therapeutic strategy for use in GBM patients.

Original languageEnglish
Pages (from-to)65125-65136
Number of pages12
JournalOncotarget
Volume7
Issue number40
DOIs
Publication statusPublished - 2016

Fingerprint

Glioblastoma
Cell Movement
Neoplasms
NF-kappa B
Cell Proliferation
Cell Migration Inhibition
Epithelial-Mesenchymal Transition
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Therapeutic Uses
Vimentin
Cadherins
Phosphatidylinositol 3-Kinases
Wound Healing
Vascular Endothelial Growth Factor A
Agar
Down-Regulation
Cell Line
Therapeutics

Keywords

  • Angiogenesis
  • Glioblastoma multiforme
  • Metastasis
  • NF-kB
  • Tumor treating fields

ASJC Scopus subject areas

  • Oncology

Cite this

Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. / Kim, Eun Ho; Song, Hyo Sook; Yoo, Seung Hoon; Yoon, Myonggeun.

In: Oncotarget, Vol. 7, No. 40, 2016, p. 65125-65136.

Research output: Contribution to journalArticle

Kim, Eun Ho ; Song, Hyo Sook ; Yoo, Seung Hoon ; Yoon, Myonggeun. / Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. In: Oncotarget. 2016 ; Vol. 7, No. 40. pp. 65125-65136.
@article{f637987434f24644a18ab74ea95c78d7,
title = "Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis",
abstract = "Treatment with alternating electric fields at an intermediate frequency (100-300 kHz), referred to as tumor treating fields (TTF) therapy, inhibits cancer cell proliferation. In the present study, we demonstrated that TTF application suppressed the metastatic potential of U87 and U373 glioblastoma cell lines via the NF-kB, MAPK and PI3K/AKT signaling pathways. Wound-healing and transwell assays showed that TTF suppressed cell migration and invasion compared with controls. Soft agar and three-dimensional culture assays showed that TTF inhibited both anchoragedependent (cell proliferation) and anchorage-independent (colony formation) GBM cell growth. TTF dysregulated epithelial-to-mesenchymal transition-related genes, such as vimentin and E-cadherin, which partially accounted for TTF inhibition of cell migration and invasion. We further demonstrated that TTF application suppressed angiogenesis by downregulating VEGF, HIF1a and matrix metalloproteinases 2 and 9. TTF also inhibited NF-kB transcriptional activity. Collectively, our findings show that TTF represents a promising novel anti-invasion and anti-angiogenesis therapeutic strategy for use in GBM patients.",
keywords = "Angiogenesis, Glioblastoma multiforme, Metastasis, NF-kB, Tumor treating fields",
author = "Kim, {Eun Ho} and Song, {Hyo Sook} and Yoo, {Seung Hoon} and Myonggeun Yoon",
year = "2016",
doi = "10.18632/oncotarget.11372",
language = "English",
volume = "7",
pages = "65125--65136",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "40",

}

TY - JOUR

T1 - Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis

AU - Kim, Eun Ho

AU - Song, Hyo Sook

AU - Yoo, Seung Hoon

AU - Yoon, Myonggeun

PY - 2016

Y1 - 2016

N2 - Treatment with alternating electric fields at an intermediate frequency (100-300 kHz), referred to as tumor treating fields (TTF) therapy, inhibits cancer cell proliferation. In the present study, we demonstrated that TTF application suppressed the metastatic potential of U87 and U373 glioblastoma cell lines via the NF-kB, MAPK and PI3K/AKT signaling pathways. Wound-healing and transwell assays showed that TTF suppressed cell migration and invasion compared with controls. Soft agar and three-dimensional culture assays showed that TTF inhibited both anchoragedependent (cell proliferation) and anchorage-independent (colony formation) GBM cell growth. TTF dysregulated epithelial-to-mesenchymal transition-related genes, such as vimentin and E-cadherin, which partially accounted for TTF inhibition of cell migration and invasion. We further demonstrated that TTF application suppressed angiogenesis by downregulating VEGF, HIF1a and matrix metalloproteinases 2 and 9. TTF also inhibited NF-kB transcriptional activity. Collectively, our findings show that TTF represents a promising novel anti-invasion and anti-angiogenesis therapeutic strategy for use in GBM patients.

AB - Treatment with alternating electric fields at an intermediate frequency (100-300 kHz), referred to as tumor treating fields (TTF) therapy, inhibits cancer cell proliferation. In the present study, we demonstrated that TTF application suppressed the metastatic potential of U87 and U373 glioblastoma cell lines via the NF-kB, MAPK and PI3K/AKT signaling pathways. Wound-healing and transwell assays showed that TTF suppressed cell migration and invasion compared with controls. Soft agar and three-dimensional culture assays showed that TTF inhibited both anchoragedependent (cell proliferation) and anchorage-independent (colony formation) GBM cell growth. TTF dysregulated epithelial-to-mesenchymal transition-related genes, such as vimentin and E-cadherin, which partially accounted for TTF inhibition of cell migration and invasion. We further demonstrated that TTF application suppressed angiogenesis by downregulating VEGF, HIF1a and matrix metalloproteinases 2 and 9. TTF also inhibited NF-kB transcriptional activity. Collectively, our findings show that TTF represents a promising novel anti-invasion and anti-angiogenesis therapeutic strategy for use in GBM patients.

KW - Angiogenesis

KW - Glioblastoma multiforme

KW - Metastasis

KW - NF-kB

KW - Tumor treating fields

UR - http://www.scopus.com/inward/record.url?scp=84994158260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994158260&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11372

DO - 10.18632/oncotarget.11372

M3 - Article

VL - 7

SP - 65125

EP - 65136

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -